Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1630
    +0.0019 (+0.16%)
     
  • GBP/USD

    1.2534
    +0.0010 (+0.08%)
     
  • Bitcoin GBP

    48,234.34
    -1,247.86 (-2.52%)
     
  • CMC Crypto 200

    1,254.81
    -103.20 (-7.60%)
     
  • S&P 500

    5,215.39
    +1.31 (+0.03%)
     
  • DOW

    39,475.58
    +87.82 (+0.22%)
     
  • CRUDE OIL

    78.40
    -0.86 (-1.09%)
     
  • GOLD FUTURES

    2,374.90
    +34.60 (+1.48%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

What Are Accelerate Diagnostics’ Key Strengths?

What Are Accelerate Diagnostics’ Key Strengths?

How Is Accelerate Diagnostics Positioned at the Start of 2018? In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock. As a result of the offering, the cash position of the company increased to $121.3 million at the end of 3Q17 as compared with $77.8 million at the end of 3Q16.